Sign up Australia
Proactive Investors - Run By Investors For Investors

Medibio bags $13.9M to progress mental health diagnosis technology

Fidelity Investments continues to maintain a 10.6% ownership in Medibio.
human brain
Fully funded to pursue commercialisation strategy

Medibio Ltd (ASX: MEB, OTCMKTS:MDBIF) has secured firm commitments to raise $13.9 million via the placement of shares at $0.36 each to institutional investors.

Fidelity Investments followed on to maintain its 10.6% ownership in Medibio with IFM Investors and Regal FM becoming substantial shareholders post-transaction.

Medibio is a mental health technology company that uses objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions.

Sleep and other circadian measures provide a powerful lens into mental wellbeing and Medibio’s solution leverages the science linking sleep and mental health.

The company is now fully funded to pursue its aggressive commercialisation and intellectual property (IP) strategy.

The new funds will allow Medibio to build out organisational infrastructure for product commercialisation and to develop the technology platform to support commercialisation.

READ NEXT: Medibio partners with Mayo Clinic to address psychiatric conditions

Earlier this month, Medibio signed a five-year clinical trial agreement with Mayo Clinic to develop new product solutions to assist physicians in addressing psychiatric conditions.

The agreement provides for the conduct of multiple clinical trials involving the use of one or more of Medibio’s proprietary products as well as assist in future product development.

Mental health represents one of the largest clinical problem today with an estimated 350 million people word-wide suffering from depression.

According to the World Bank, depression and anxiety disorders cost the world nearly US$1 trillion annually.

View full MEB profile View Profile

Medibio Ltd Timeline

October 11 2017
November 18 2016
November 16 2016

Related Articles

March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
December 18 2017
VAL201 is a treatment for metastatic prostate cancer and other solid tumours
Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use